ALPHARETTA, Ga.–(BUSINESS WIRE)–Cartiva, Inc., a developer of innovative products for the treatment of cartilage damage and osteoarthritis, announced today that it received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its Cartiva Synthetic Cartilage Implant (SCI) for arthritis of the big toe joint. The approval allows the Company to begin marketing …
ALPHARETTA, Ga.–(BUSINESS WIRE)–Cartiva, Inc., a developer of innovative products for the treatment of
cartilage damage and osteoarthritis, announced today that it received
Premarket Approval (PMA) from the U.S. Food and Drug Administration
(FDA) for its Cartiva Synthetic Cartilage Implant (SCI) for arthritis of
the big toe joint. The approval allows the Company to begin marketing in
the United States the first synthetic cartilage device approved by the
Cartiva SCI is intended for the treatment of painful arthritis at the
base of the big toe, the most common arthritic condition in the foot.
The current standard of care involves fusing the bones in the arthritic
joint with screws and plates. While fusion is an effective procedure for
eliminating pain, it permanently prevents movement of the joint.
The Cartiva SCI device, an alternative to fusion, is a biocompatible,
biomedical polymer implant designed to have physical properties similar
to those of articular cartilage. Damaged cartilage is replaced with a
small Cartiva SCI implant that provides a cartilage-like compressible,
low-friction and durable bearing surface. The implant provides pain
relief and improves both function and motion.
The FDA’s decision was supported by the MOTION clinical study, a
236-patient, multi-center, prospective, randomized study comparing
Cartiva SCI to fusion – the largest study ever conducted for this
Key findings from the Level I clinical study include:
- The Cartiva patient group demonstrated clinical success of 80% for the
composite primary endpoint (pain, function and safety) at 24 months
compared to 79% success for the fusion group
- Cartiva patients achieved a 93% reduction in median pain
- Cartiva patients demonstrated a 168% improvement in median function of
sporting activities and 65% improvement in activities of daily living
- Cartiva patients experienced a 26% improvement in range of motion from
“The landmark MOTION study clearly shows Cartiva SCI to be a safe and
effective alternative to fusion for patients wishing to maintain motion
in their great toe,” said Dr. Judith Baumhauer, Professor and Associate
Chair of Academic Affairs, University of Rochester Medical Center, and
Principal Investigator on the MOTION study. “Based on these compelling
results, I have eagerly awaited the FDA approval and the ability to
offer this treatment option to my patients.”
Cartiva SCI has been approved for use outside the United States since
2002 and is currently available in Europe, Canada and Brazil. To date,
more than 4,000 implants have been used. It is performed in a simple
outpatient procedure lasting approximately 35 minutes. Unlike a fusion
procedure, patients may begin weight bearing immediately as tolerated.
“Before Cartiva SCI, the options we could provide to patients with
osteoarthritis of the great toe were limited, as the fusion procedure
often necessitates sacrificing range of motion to get pain relief,” said
Dr. Mark Glazebrook of the Queen Elizabeth II Health Sciences Centre in
Halifax, Nova Scotia, who uses Cartiva SCI in his practice. “Due to the
simplicity of the procedure, speed of recovery and range of motion
benefits, I see that patients are relieved to have this option available
to them and the majority are electing Cartiva over fusion.”
“We are thrilled with the approval of Cartiva SCI and appreciate the
hard work and collaboration of the U.S. Food and Drug Administration
orthopaedic branch. We’re grateful to our clinical investigators, their
study coordinators and, of course, our patients in helping us reach this
critical milestone,” said Tim Patrick, president and CEO, Cartiva, Inc.
“We look forward to introducing Cartiva SCI at the American Orthopaedic
Foot and Ankle Society Annual Meeting in Toronto later this month.”
About Cartiva, Inc.
Based in Alpharetta, Ga., Cartiva, Inc. develops and markets innovative
solutions for patients with cartilage damage and osteoarthritis.
Cartiva’s venture investors include New Enterprise Associates, Windham
Venture Partners and Domain Associates. Additional information is
available on the company’s website at www.cartiva.net.